OptimizeRx (OPRX) Receivables - Other (2016 - 2026)

OptimizeRx has disclosed Receivables - Other across 10 years of filings, most recently posting $3.9 million for Q2 2026.

• In Q2 2026, Receivables - Other rose 12.55% year-over-year to $3.9 million; the TTM figure through Jun 2026 stood at $3.9 million (up 12.55% YoY), while the FY2025 annual figure was $3.9 million, up 21.66% from the prior year.
• Receivables - Other came in at $3.9 million for Q2 2026 at OptimizeRx, down from $4.7 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $6.1 million in Q4 2023 to a low of $3.2 million in Q4 2024.
• Average Receivables - Other over 5 years is $4.3 million, with a median of $3.9 million recorded in 2025.
• Year-over-year, Receivables - Other jumped 69.73% in 2022 and tumbled 46.67% in 2024.
• Over 5 years, Receivables - Other stood at $3.6 million in 2022, then surged by 69.62% to $6.1 million in 2023, then sank by 46.67% to $3.2 million in 2024, then gained by 21.66% to $3.9 million in 2025, then slipped by 0.58% to $3.9 million in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $3.9 million in Q2 2026, $4.7 million in Q1 2026, and $3.9 million in Q4 2025.